Drug Trial Radar · NCT00289588
An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers
Last checked: Nov 20, 2026Latest source record: Feb 16, 2006 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,000
Actual
Start
Jan 2005
Primary completion
Not stated
Study completion Dec 2005
Sponsor
- Lead sponsor
- Brooke Army Medical CenterFederal agency
- Sponsor type
- Federal agency
- Collaborators
- GlaxoSmithKline; Becton, Dickinson and Company
- First posted
- Feb 10, 2006
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- All sexes, from 17 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main purpose of this study is to determine if applying mupirocin into soldiers noses who are colonized with methicillin-resistant Staphylococcus aureus (MRSA) will reduce infections in them and their cohort of fellow soldiers.
Conditions
- Community-Acquired MRSA Infections
- Abscesses
- Cellulitis
- Folliculitis
Interventions
Mupirocin (drug)Drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Soft tissue infections in subjects who received the study medication and soft tissue infections in the study cohorts.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Brooke Army Medical Center
Fort Sam Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.